Review
Erythropoietin, an update, and where to in the future?
Affiliations
- PMID: 10392076
Item in Clipboard
Review
Erythropoietin, an update, and where to in the future?
EDTNA ERCA J.
1998 Jul-Sep.
Abstract
Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anaemia associated with renal failure. This paper discusses basic principles for its administration, potential side effects and strategies for non response to erythropoietin (Epo) therapy.
Similar articles
-
Finding a rational approach to ESA therapy--for payers and patients.Nephrol News Issues. 2007 Sep;21(10):54, 56. Nephrol News Issues. 2007. PMID: 17918481 No abstract available.
-
Erythropoietin: mechanisms of action and indications for treatment.Neth J Med. 1993 Jun;42(5-6):187-202. Neth J Med. 1993. PMID: 8377877 Review.
-
Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.Med Hypotheses. 2012 Jan;78(1):157-61. doi: 10.1016/j.mehy.2011.10.016. Epub 2011 Nov 10. Med Hypotheses. 2012. PMID: 22078846
-
Management of the anaemia of chronic renal failure with recombinant erythropoietin.Q J Med. 1989 Dec;73(272):1093-101. Q J Med. 1989. PMID: 2694210 Review. No abstract available.
-
Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?ASAIO J. 1993 Jan-Mar;39(1):11-8. ASAIO J. 1993. PMID: 8439674 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials